A prospective study of the efficacy of oral propranolol in reduction of
the frequency and severity of epistaxis in Hereditary Haemorrhagic
Telangiectasia
Abstract
1) This pilot trial demonstrated utility of oral propranolol in
management of epistaxis in HHT 2) Propranolol was effective in reducing
the severity and frequency of nosebleeds in HHT, as measured by the
epistaxis severity scale, and this improvement is mirrored by an
improvement in global quality of life 3) Adverse effects were
experienced by a minority of patients, with the most significant event
being pitting oedema 4) Following cessation of treatment, patients
demonstrated a trend of regression with worsening of epistaxis scores 5)
Further investigation is justified by its favourable effects, wide
availability, and minimal side effect profile